EBS Technologies | Updates

By Team EBS Technologies

How the EBS NEXT WAVE Technology Works


Dear Companists,

Several comments have shown us that many of you are very interested in our therapy method and in its mechanism of action. Consequently, we would like to explain the medical details to you in today's update.

Our visual system consists not only of the eyes, but also of the optic nerve and the visual cortex, which is located in the rear area of the human brain. Signals that reach the eyes are transmitted from the retina to the optic nerve and on to the visual cortex, where visual perception – or vision – finally takes place.


Damage occurring within this complex system may result in visual field loss. Visual field loss may take several forms, some of them even leading to complete blindness in patients.

Such visual impairments may have various reasons. In the case of glaucoma, for instance, high pressure within the eye usually causes gradual neuronal death within the retina and the optic nerve, which in turn causes signal transmission to the visual cortex to be impaired. The result is visual field loss, which patients often perceive as tunnel vision.

Other causes of visual impairments can be traumatic brain injuries or strokes. If damage occurs, for example, within the visual cortex, the brain is no longer able to correctly process all visual signals it receives. Thus, in such cases, patients often suffer from visual field impairments even though their eyes and optic nerve are intact.

In other words, the causes of visual impairments could not be more diverse, yet they have one thing in common: They are all due to neurological damage within the visual system.

This is precisely where the EBS therapy method comes into play: The method's stimulation signals, which are perfectly tailored to each patient's individual needs, may alleviate visual impairments whose causes are located behind the eyes (neurological causes).


Video Explaining the EBS NEXT WAVE™ System


Electrical Brain Synchronization 

Did you know that EBS is short for Electrical Brain Synchronization?

These three terms summarize our therapy method's mechanism of action very well. Indeed, using electrical impulses, we can stimulate neurons in the visual system and in the brain. As a result of electrical stimulation, neurons may synchronize.

To explain this phenomenon in more detail, we believe traumatic brain injuries (which, for instance, occur after accidents) can be a helpful example. Because of injuries, for instance in the visual cortex of the brain, a large number of neurons may die and be lost forever. In many of such cases, a number of neurons survive and remain fully functional, yet they lose their communication partners – the neighboring neurons. Consequently, these surviving neurons are also called silent neurons. If silent neurons are stimulated by means of low alternating currents, they are excited and start transmitting signals themselves again. Thus, the result may be new connections with other neurons or even with other intact brain areas – a process that is called neuro-synchronization.

But this is not the only thing the EBS therapy method can do. In addition to the reintegration of silent neurons into a functioning network, there is a second aspect that improves the efficacy of our therapy method: It prevents that additional neurons die.

Glaucoma is a particularly helpful example of this aspect. This is due to the fact that glaucoma not only causes neurons to die, but also causes them to die slowly and continuously, i.e., that it is a degenerative illness. In glaucoma patients, alternating current therapy may stimulate the metabolism of dying neurons and thus stabilize these cells. As a result, the neurons are enabled to transmit signals again. In medical contexts, this process is called neuroprotection.

Both of the above mechanisms of action thus enable therapy centers to help many patients suffering from visual field loss. Even small improvements may alleviate the visual impairments of such patients.


EBS from a Patient's Perspective

In May 2014, the Australian Peter R. underwent treatment with our therapy method and told us afterward:

"Immediately after treatment, I felt that something had changed. Back in Australia, my doctor confirmed this feeling. Both in terms of visual acuity and in terms of my visual field, tests showed clear improvements. In practical terms, this means that I can see my piano keys more clearly again and read the buttons on my computer keyboard without moving my head back and forth. Also, I no longer have to feel the edge of a glass when filling it, and watching TV finally makes sense again. I am really glad that I had the opportunity to undergo this new kind of treatment."

This success is made possible primarily by the precise adaptation of stimulation parameters to the patient, which is done by using a unique and patented combination of EEG and electrical stimulation.

We hope that this update has provided you with some new insights into the fascinating world of the EBS therapy method, and we are looking forward to your questions and comments.

The EBS Technologies team


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 258,825


€ 329

Average Investment

3.67 %

Share Offered

Please note
The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 6 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of EBS Technologies.
Already registered?    Log in